Current stock page

Stock Analysis

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis

BioCryst Pharmaceuticals, Inc. (BCRX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

BCRX Stock Analysis Summary

BioCryst Pharmaceuticals, Inc. (BCRX) currently has an AIQ Score of 59/100, indicating a neutral setup. Value is the strongest factor at 86/100. Momentum is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

BCRX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$7.61
AIQ Score59/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$1.95B
P/E Ratio (TTM)-5.64
Forward P/E—
EPS (Q3 FY2026)$0.15
Revenue (Q3 FY2026)$180.29M
Dividend Yield (TTM)0.00%
Beta0.65
Volume2.32M
52-week range$6.23-$11.22
RSI 1440.74
50-Day SMA$8.23
200-Day SMA$8.80
Analyst Price Target$11.00
Next EarningsFeb 25, 2027
As of Nov 13, 2026 · Market close

BCRXBioCryst Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$7.61−$0.07 (−0.91%)

Latest quote

  • Momentum
    42
  • Value
    86
  • Quality
    64
  • Risk resilience
    55
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

BCRX Stock Analysis Summary

BioCryst Pharmaceuticals, Inc. (BCRX) currently has an AIQ Score of 59/100, indicating a neutral setup. Value is the strongest factor at 86/100. Momentum is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, BCRX has AIQ Score of 59/100 with Value base of 86/100 and fading Momentum at 42/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Value (86/100) leads while Momentum (42/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.91% stock move · BCRX classified in Biotechnology.

Current Evidence

NeutralBCRX is in a neutral AIQ regime; Value is the strongest visible factor at 86/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is BCRX Bullish or Bearish Right Now?

BCRX currently has a neutral overall setup. Value is the strongest factor at 86/100, while Momentum is weakest at 42/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Analyst target implies +44.55% upside from the latest quote.
Bear Case
  • - Momentum is weak at 42/100.
  • - Price is -13.53% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (34 vs 7).

Current Consensus

BCRX's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 5 neutral, and 34 sell votes. BCRX's 14-day RSI is 40.74, which places the stock in a weaker momentum range. BCRX's beta is 0.65, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in BCRX?

The largest recent change in BCRX is Momentum moving down by 10.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
-3.0
Momentum
-10.0
Quality
+1.0
Risk
+1.0

What Would Change the BCRX Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

BCRX Decision Framework

Public evidence layers, setup checks, and risk context for BioCryst Pharmaceuticals, Inc..

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis

BioCryst Pharmaceuticals, Inc. has an AIQ Score of 59/100 in a Neutral regime. Value is strongest at 86/100. Beta is 0.65, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextBCRX is in a Neutral AIQ regime with score 59/100.
Signal ConflictThe primary conflict is that value leads at 86/100 while momentum lags at 42/100.
Factor EvidenceMomentum 42/100 · Value 86/100 · Quality 64/100 · Risk 55/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Value is the strongest factor at 86/100.

TimingFail

Momentum is 42/100 and RSI (14) is 40.7.

Regime fitWait

BCRX is in a Neutral regime at 59/100.

Risk controlWait

Risk factor is 55/100 with beta 0.65 and annual volatility 48.06%.

ConflictWait

Current conflict: value leads at 86/100 while momentum lags at 42/100.

AIQ Score
59/100
Price
$7.61
Beta
0.65
RSI (14)
40.7

BCRX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

BCRX Fundamentals

BCRX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$180.29M
Net income
$37.92M
Free cash flow
$32.75M
View full BCRX fundamental analysis

BCRX Technical Analysis

BCRX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
40.74
Price vs SMA-50
-7.56%
View full BCRX technical analysis

BCRX Stock Catalysts

Track BCRX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 25, 2027
Analyst target
$11.00
News items
5
View BCRX earnings and stock catalysts

BCRX Dividend Analysis

BCRX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View BCRX dividend history and analysis

BCRX Financial Data

BCRX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$180.29M
EPS
$0.15
Periods
8
View BCRX financials

BCRX Risk Analysis

BCRX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.65
Risk score
55/100
1Y volatility
48.06%
View BCRX risk analysis

BCRX Stock News

BCRX stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read BCRX stock news

BCRX vs Biotechnology Peers

Current peer cohort: BCRX · BHVN · BLTE · CAI · CAPR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
BCRX
Current stock
59/10086/10042/10055/1000.3648.06%Current
BHVN
Biohaven Ltd.
47/100—78/10035/100182.98%BCRX vs BHVN
BLTE
Belite Bio, Inc
74/100—71/10060/1000.953.71%BCRX vs BLTE
CAI
Caris Life Sciences, Inc.
70/10068/10085/10036/1000.2269.82%BCRX vs CAI
CAPR
Capricor Therapeutics, Inc.
38/100—45/10016/1000.93395.16%BCRX vs CAPR
Pairwise Compare links: BHVN · BLTE · CAI · CAPRBCRX vs BHVNBCRX vs BLTEBCRX vs CAIBCRX vs CAPRCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a BCRX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for BCRX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-5.64
As of Nov 13, 2026
Revenue growth
13.11%
Gross margin
25.28%
Current debt / equity
-2.08
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$180.29M
Quarter net income
$37.92M
Quarter free cash flow
$32.75M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Bearish
RSI 14
40.74
MACD
-0.18

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
55/100
Beta
0.65
Annual volatility
48.06%
Max drawdown
-32.22%

BCRX Stock FAQ

What is BCRX stock price today?

BioCryst Pharmaceuticals, Inc.'s current stock price is $7.61. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is BCRX bullish or bearish right now?

BCRX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is BCRX's market cap?

BCRX's market cap is $1.95B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is BCRX's current P/E ratio?

BCRX's current P/E ratio is -5.64 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is BCRX's RSI?

BCRX's 14-day RSI is 40.74 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is BCRX above its 50-day and 200-day moving averages?

BCRX is -7.56% from its 50-day SMA and -13.53% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is BCRX's next earnings date?

BCRX's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does BCRX pay a dividend?

BCRX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.